Respiratory Syncytial Virus (RSV) is a common virus that infects children and adults;
however, children younger than two years of age tend to develop more serious respiratory …

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract
infections in infants and young children, accounting for more than 100,000 hospitalizations …

Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants,
young children, and older or immunocompromised adults. Although aerosolized ribavirin …

Respiratory syncytial virus (RSV) is a common and highly contagious pathogen that infects
nearly all children by the age of 2 years. It is responsible for significant morbidity and …

Respiratory syncytial virus (RSV) is an important respiratory pathogen in infants and children
worldwide. Although RSV typically causes mild upper respiratory infections, it frequently …

Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus
(RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children …

Respiratory syncytial virus (RSV) remains a significant cause of morbidity and mortality in
infants, immunocompromised patients and the elderly. Despite the high disease burden, an …

Respiratory syncytial virus (RSV) infects nearly all children by age 2 years, and it causes
considerable illness and death in certain high-risk pediatric populations. Historically …

In this review, we describe the history, epidemiology and clinical manifestations of infections
attributed to respiratory syncytial virus (RSV) in children. At present, no cure exists for RSV …

Respiratory syncytial virus (RSV) is responsible for a large burden of disease globally and
can present as a variety of clinical syndromes in children of all ages. Bronchiolitis in infants …